Targeting p19 in psoriatic arthritis: more than just another therapeutic approach?

Lancet. 2020 Apr 4;395(10230):1091-1093. doi: 10.1016/S0140-6736(20)30525-0. Epub 2020 Mar 13.

Authors

Andreas Kerschbaumer¹, Daniel Aletaha²

Affiliations

¹ Department of Medicine III, Division of Rheumatology, Medical University of Vienna, 1090 Vienna, Austria. Electronic address: andreas.kerschbaumer@meduniwien.ac.at.
² Department of Medicine III, Division of Rheumatology, Medical University of Vienna, 1090 Vienna, Austria.

PMID: 32178770
DOI: 10.1016/S0140-6736(20)30525-0

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Arthritis, Psoriatic*
Biological Products*
Double-Blind Method
Humans
Tumor Necrosis Factor-alpha

Substances

Antibodies, Monoclonal, Humanized
Biological Products
Tumor Necrosis Factor-alpha
guselkumab